Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Exonics Using CRISPR To Develop One-Time Treatment for Duchenne

Executive Summary

Newly formed biotech company hopes to avoid patent melee and use gene editing technology to develop therapy for up to 80% of boys with DMD; trial outcomes to drive terms of future licensing deals.

Advertisement

Related Content

US FDA's Authority Over CRISPR Is Adequate, NASEM Finds, But Off-Label Challenge May Emerge
UC's CRISPR Licensees Unbowed By Losing Initial US Patent Office Ruling
Amid Pricing Criticism, Marathon 'Pausing' Emflaza Launch
CRISPR Companies Form Pact To Defend, Cross-License Gene Editing Patents
Scrip's Rough Guide To CRISPR Gene Editing

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS120119

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel